The World Health Organization’s (WHO’s) approval for WHO pre-qualification or Emergency Use Listing (EUL) for Bharat Biotech International Ltd’s covid-19 vaccine is moving according to procedure and the Indian government’s haste in pushing through the process is only adding to speculation about the alleged delay.
The delay in India’s indigenous vaccine getting emergency use authorization is because WHO has raised some more questions on Covaxin and the queries have been sent to Bharat Biotech for further clarification.
As per the World Health Organisation, it is waiting for an additional piece of information from the Hyderabad-based biotechnology company before it evaluates the vaccine
If Bharat Biotech’s Covaxin gets the approval, those inoculated with the vaccine can travel to countries that permit entry of fully vaccinated people. The company can also export it to countries that use vaccines approved by WHO.
The WHO Emergency Use Listing Procedure (EUL) is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency